A citation-based method for searching scientific literature

Peter Schmid, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A Fasching, Fatima Cardoso, Jay Andersen, Debra Patt, Michael Danso, Marta Ferreira, Marie-Ange Mouret-Reynier, Seock-Ah Im, Jin-Hee Ahn, Maria Gion, Sally Baron-Hay, Jean-François Boileau, Yu Ding, Konstantinos Tryfonidis, Gursel Aktan, Vassiliki Karantza, Joyce O'Shaughnessy. N Engl J Med 2022
Times Cited: 111

F Poggio, M Bruzzone, M Ceppi, N F Pondé, G La Valle, L Del Mastro, E de Azambuja, M Lambertini. Ann Oncol 2018
Times Cited: 196

List of shared articles

Times cited

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Elisa Agostinetto, Agnese Losurdo, Guilherme Nader-Marta, Armando Santoro, Kevin Punie, Romualdo Barroso, Lazar Popovic, Cinzia Solinas, Marleen Kok, Evandro de Azambuja,[...]. Expert Opin Investig Drugs 2022

Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.
Jyoti Bajpai, Lakhan Kashyap, Dilip Harindran Vallathol, Ankita Das, Maneesh Singh, Rima Pathak, Sushmita Rath, Anbarasan Sekar, Subham Mohanta, Asha Reddy,[...]. Breast 2022

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
Laura M Spring, Yael Bar, Steven J Isakoff. J Natl Compr Canc Netw 2022

Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?
Federica Giugliano, Carmine Valenza, Paolo Tarantino, Giuseppe Curigliano. Expert Opin Investig Drugs 2022

Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies.
Isaiah MacDonald, Nancy A Nixon, Omar F Khan. Curr Oncol 2022

Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications.
Karama Asleh, Nazia Riaz, Torsten O Nielsen. J Exp Clin Cancer Res 2022

Breast cancer: an up-to-date review and future perspectives.
Ruoxi Hong, Binghe Xu. Cancer Commun (Lond) 2022

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.
Giovanna Garufi, Luisa Carbognin, Francesco Schettini, Elia Seguí, Alba Di Leone, Antonio Franco, Ida Paris, Giovanni Scambia, Giampaolo Tortora, Alessandra Fabi. Cancers (Basel) 2022

Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report.
Diego Gomez-Puerto, Alba Llop-Guevara, Mara Cruellas, Sara Torres-Esquius, Javier De La Torre, Vicente Peg, Judith Balmaña, Isabel Pimentel. Front Oncol 2022

Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
William Jacot, Amélie Lusque, Cécile Vicier, Audrey Mailliez, Thibault de La Motte Rouge, Luc Cabel, Christelle Levy, Anne Patsouris, Isabelle Desmoulins, Lionel Uwer,[...]. Br J Cancer 2022

Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis.
Ying-Yi Lin, Hong-Fei Gao, Xin Yang, Teng Zhu, Xing-Xing Zheng, Fei Ji, Liu-Lu Zhang, Ci-Qiu Yang, Mei Yang, Jie-Qing Li,[...]. Breast 2022

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.
Elisa Agostinetto, Flavia Jacobs, Véronique Debien, Alex De Caluwé, Catalin-Florin Pop, Xavier Catteau, Philippe Aftimos, Evandro de Azambuja, Laurence Buisseret. Cancers (Basel) 2022